News

AddToAny

Google+ Facebook Twitter Twitter

Artificial enzymes programmed to destroy SARS-CoV-2

Cambridge scientists have used synthetic biology to create artificial enzymes programmed to target the genetic code of SARS-CoV-2 and destroy the virus.

The approach could be used to develop a new generation of antiviral drugs, they said.

In 2014, Dr Alex Taylor and colleagues discovered that artificial genetic material known as XNA – in other words, synthetic chemical alternatives to RNA and DNA not found in nature – could be used to create the world’s first fully-artificial enzymes, which Taylor named XNAzymes.

At the beginning, XNAzymes were inefficient, requiring unrealistic laboratory conditions to function.

Earlier this year, however, his lab reported a new generation of XNAzymes, engineered to be much more stable and efficient under conditions inside cells. These artificial enzymes can cut long, complex RNA molecules and are so precise that if the target sequence differs by just a single nucleotide (the basic structural unit of RNA), they will recognise not to cut it. This means they can be programmed to attack mutated RNAs involved in cancer or other diseases, leaving normal RNA molecules well alone.

Now, in research published in Nature Communications, Taylor and his team at the Cambridge Institute of Therapeutic Immunology and Infectious Disease at the University of Cambridge report how they have used this technology to successfully “kill” live SARS-CoV-2 virus.

bit.ly/3EcIrpx

Image credit | iStcok

Related Articles

The big question: Are we entering a new era in which mRNA vaccines are the future?

In May, AstraZeneca began the worldwide withdrawal of its COVID-19 vaccine, due to a “surplus of updated vaccines” that target new variants. Then in June, Moderna announced positive late-stage trial results for its single COVID/flu combination vaccine, mRNA-1083. On the back of this, we look at the future impact of mRNA vaccines.

Breast cancer CREDIT - Science Photolibrary- C0584739

Predicting the return of breast cancer

Dr Isaac Garcia-Murillas discusses a new blood test that can predict if breast cancer will return years before the disease shows on scans.

Restless leg syndrome - CREDIT Science Photolibrary- C0309748

Study points to potential treatments for restless leg syndrome

Scientists have discovered genetic clues to the cause of restless leg syndrome. The discovery could help identify those individuals at greatest risk of the condition and point to potential ways to treat it.

Stem cell transplant and cellular therapy lab

My lab: stem cell transplant and cellular therapy lab

Advanced Specialist Biomedical Scientist Mel Green gives a guided tour of the stem cell transplant lab at Nottingham University Hospitals.

Top